Bioxytran Inc., a clinical-stage biotechnology company, has entered into a sponsored research collaboration with the University of Minnesota to advance the development of novel carbohydrate-based therapeutics. The partnership will focus on improving the understanding of polysaccharide and oligosaccharide interactions with biologically relevant targets. Under the agreement, research will be conducted at the University of Minnesota under the leadership of Dr. Kevin Mayo, an expert in biomolecular structure and nuclear magnetic resonance spectroscopy. Bioxytran will fund the project, which is expected to run through early 2027, while retaining broad rights to use the resulting research data for internal research and development. The University of Minnesota will maintain ownership of any intellectual property generated during the collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646822) on February 02, 2026, and is solely responsible for the information contained therein.